{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:02:17Z","timestamp":1777611737100,"version":"3.51.4"},"reference-count":25,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Fukujuji Hospital"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.resinv.2019.10.007","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T12:56:26Z","timestamp":1576500986000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations"],"prefix":"10.1016","volume":"58","author":[{"given":"Masao","family":"Okumura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Yoshiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideo","family":"Ogata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsuyuki","family":"Kurashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kozo","family":"Yoshimori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shoji","family":"Kudoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2019.10.007_bib1","series-title":"Towards universal access to diagnosis and treatment of multi-drug resistant and extensively drug resistant by 2015: WHO progress report","author":"World Health Organization","year":"2011"},{"key":"10.1016\/j.resinv.2019.10.007_bib2","series-title":"Anti-tuberculosis drug- resistance in the world report no.4","author":"World Health Organization","year":"2008"},{"issue":"3","key":"10.1016\/j.resinv.2019.10.007_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1183\/09031936.00073611","article-title":"WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update","volume":"38","author":"Falzon","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.resinv.2019.10.007_bib4","series-title":"Guidelines for the Programmatic management of drug-resistant tuberculosis","author":"World Health Organization","year":"2008"},{"issue":"9","key":"10.1016\/j.resinv.2019.10.007_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.resinv.2019.10.007_bib6","first-page":"153","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis Lancet","volume":"9","author":"Orenstein","year":"2009","journal-title":"Inf Disp"},{"issue":"3","key":"10.1016\/j.resinv.2019.10.007_bib7","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1183\/09031936.00003710","article-title":"Treatment outcome of multidrug\/extensively drug-resistant tuberculosis in Latvia, 2000-2004","volume":"36","author":"Leimane","year":"2010","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.resinv.2019.10.007_bib8","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1056\/NEJMoa022928","article-title":"Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru","volume":"348","author":"Mitnick","year":"2003","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.resinv.2019.10.007_bib9","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug \u2013 resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenatein","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.resinv.2019.10.007_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0006914","article-title":"Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"4","author":"Johnston","year":"2009","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.resinv.2019.10.007_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001300","article-title":"Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients","volume":"9","author":"Ahuja","year":"2012","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.resinv.2019.10.007_bib12","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1183\/09031936.00168008","article-title":"Epidemiology and clinical management of XDR-TB: a systematic review by TBNET","volume":"33","author":"Sotgiu","year":"2009","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.resinv.2019.10.007_bib13","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1086\/653115","article-title":"Treatment outcomes among patients with extensively drug- resistant tuberculosis: systematic review and meta-analysis","volume":"51","author":"Jacobson","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"10.1016\/j.resinv.2019.10.007_bib14","first-page":"679","article-title":"About using of delamanid. (Article in Japanese)","volume":"89","year":"2014","journal-title":"Kekkaku"},{"issue":"11","key":"10.1016\/j.resinv.2019.10.007_bib15","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydro- imidazooxazole derivative with promising action against tuberculosis in\u00a0vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"10.1016\/j.resinv.2019.10.007_bib16","series-title":"WHO treatment guidelines for drug-resistant tuberculosis 2016 update. October 2016 revision","author":"World Health Organization","year":"2016"},{"key":"10.1016\/j.resinv.2019.10.007_bib17","series-title":"Rapid Communication: key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). August 2018","author":"World Health Organization","year":"2018"},{"issue":"1","key":"10.1016\/j.resinv.2019.10.007_bib18","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1128\/AAC.47.1.416-417.2003","article-title":"In\u00a0vitro activities of linezolid against clinical isolates of Mycobavterium tuberculosis that are susceptible or resistant to first-line antituberculous drugs","volume":"47","author":"Alcala","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"issue":"23","key":"10.1016\/j.resinv.2019.10.007_bib19","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.resinv.2019.10.007_bib20","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur respire J"},{"issue":"12","key":"10.1016\/j.resinv.2019.10.007_bib21","first-page":"805","article-title":"Treatment of multi-drug resistant tuberculosis in Japan","volume":"77","author":"Nakajima","year":"2002","journal-title":"Kekkaku"},{"issue":"1","key":"10.1016\/j.resinv.2019.10.007_bib22","first-page":"71","article-title":"About using of Bedaquiline","volume":"93","year":"2018","journal-title":"Kekkaku"},{"issue":"8","key":"10.1016\/j.resinv.2019.10.007_bib23","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.resinv.2019.10.007_bib24","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.resinv.2019.01.001","article-title":"Safety, efficacy, and pharmacokinetics of bedaquiline in Japanese patients with pulmonary multidrug-resistant tuberculosis: an interim analysis of an open-label, phase 2 study","volume":"57","author":"Tsuyuguchi","year":"2019","journal-title":"Respir Investig"},{"issue":"10","key":"10.1016\/j.resinv.2019.10.007_bib25","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.3201\/eid2310.170468","article-title":"Six-month response to delamanid treatment in MDR-TB patients","volume":"23","author":"Hewison","year":"2017","journal-title":"Emerg Infect Dis"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534519301601?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534519301601?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:29:10Z","timestamp":1761949750000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534519301601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S2212534519301601"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2019.10.007","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of multidrug-resistant pulmonary tuberculosis with delamanid based on Japanese guideline recommendations","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2019.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}